|
|
|
16 Jan 2008 |
New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents
|
|
15 Jan 2008 |
BioInvent and Genentech Initiate Phase I Clinical Trial for BI-204, a potential treatment for cardiovascular conditions associated with atherosclerosis
|
|
15 Jan 2008 |
Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy
|
|
15 Jan 2008 |
Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
|
|
15 Jan 2008 |
ZymoGenetics Announces Special Protocol Assessment for Atacicept in General SLE
|
|
14 Jan 2008 |
FDA Approves TYSABRI(R) For The Treatment Of Moderate-To-Severe Crohn's Disease
|
|
09 Jan 2008 |
TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric Antibody
|
|
08 Jan 2008 |
Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
|
|
08 Jan 2008 |
Medarex Announces Allowance of Investigational New Drug Application for Wholly Owned Fully Human Anti-CD70 Antibody, MDX-1411
|
|
08 Jan 2008 |
Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech
|
|
07 Jan 2008 |
Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma
|
|
04 Jan 2008 |
Genmab Announces HuMax-CD32B Pre-Clinical Program
|
|
03 Jan 2008 |
Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies
|
|
03 Jan 2008 |
ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer Compounds
|
|
03 Jan 2008 |
Expanded Labeling for MabCampath(R) in Europe
|
|
30 Dec 2007 |
MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of its MOR103 Program
|
|
22 Dec 2007 |
Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer's Disease
|
|
21 Dec 2007 |
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
|
|
21 Dec 2007 |
Fresenius Biotech applies for the marketing authorization of the trifunctional antibody Removab (R) for the treatment of malignant ascites
|
|
20 Dec 2007 |
Ablinx Extends Agreement With Wyeth
|
|
20 Dec 2007 |
Human Genome Sciences initiates second randomized Phase 2 trial of HGS- ETR 1 in combination with chemotherapy
|
|
20 Dec 2007 |
R1507 antibody to enter Phase II study to treat sarcoma
|
|
20 Dec 2007 |
Abbott's HUMIRA (R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
|
|
19 Dec 2007 |
Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer
|
|
17 Dec 2007 |
Auxilium Pharmaceuticals, Inc. Completes Enrollment in Two Phase III Clinical Trials of XIAFLEX(TM) for Dupuytren's Contracture
|
|
17 Dec 2007 |
Ablynx Reports Positive Phase I Results for Its Anti-Thrombotic Nanobody(R), ALX-0081
|
|
14 Dec 2007 |
Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy
|
|
13 Dec 2007 |
WILEX announces positive result of the interim analysis for futility of its Phase III ARISER trial with RENCAREX(R)
|
|
13 Dec 2007 |
Merck Announces Initiation of Phase II/III Clinical Trial of Atacicept in Lupus Nephritis
|
|
13 Dec 2007 |
Genmab announces details of planned Ofatumumab Phase II study in multiple sclerosis
|
|
13 Dec 2007 |
Genmab initiates Ofatumumab Phase II study in diffuse large b-cell lymphoma
|
|
11 Dec 2007 |
ThromboGenics Presents Results of the Phase I Trial of TB-402 at thePrestigious American Society of Hematology Annual Meeting
|
|
11 Dec 2007 |
Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
|
|
10 Dec 2007 |
Seattle Genetics Reports Multiple Complete Remissions With SGN-33 in Acute Myeloid Leukemia at ASH
|
|
10 Dec 2007 |
GlaxoSmithKline and OncoMed Pharmaceuticals Form Strategic Alliance to Develop Cancer Stem Cell Antibody Therapeutics
|
|
10 Dec 2007 |
Genitope Corporation Presents New Data On Its Therapeutic Monoclonal Antibodies To Potentially Treat B-Cell Malignancies
|
|
10 Dec 2007 |
MorphoSys Broadens Scope of Collaboration with GeneFrontier
|
|
10 Dec 2007 |
PDL BioPharma Presents Data on Novel Monoclonal Antibody for Multiple Myeloma at the 2007 American Society of Hematology Annual Meeting
|
|
10 Dec 2007 |
Ablynx announces extension of Nanobody (R) drug discovery and development alliance
|
|
10 Dec 2007 |
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
|
|
10 Dec 2007 |
Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin's Lymphoma
|
|
10 Dec 2007 |
Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
|
|
10 Dec 2007 |
Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
|
|
10 Dec 2007 |
Biolex Researchers Present Results of Anti-CD20 Antibody With Optimized Glycosylation at ASH Conference
|
|
09 Dec 2007 |
ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting for TAP Compound AVE9633
|
|
08 Dec 2007 |
ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting with Targeted Anticancer Compounds IMGN901 (HuN901-DM1) and AVE1642
|
|
07 Dec 2007 |
Genmab's HuMax-CD38 Enters Phase I/II Clinical Trial For Multiple Myeloma
|
|
07 Dec 2007 |
Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination with Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
|
|
06 Dec 2007 |
Raven biotechnologies, Inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
|
|
05 Dec 2007 |
Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
|
| |
|
Results 251 - 300 of 1043 |
